Originally published as JCO Early Release 10.1200/JCO.2005.08.128 on January 24 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martinelli, G. Articles by Zucca, E. Search for Related Content PubMed PubMed Citation Articles by Martinelli, G. Articles by Zucca, E. Social Bookmarking                            What's this?

Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy

From the European Institute of Oncology; Hospital San Raffaele, Milan, Italy; Pathology Institute, Locarno; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Address reprint requests to Daniele Laszlo, MD, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy; e-mail: daniele.laszlo{at}ieo.it

PURPOSE: Preliminary results using rituximab in extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients seem to indicate a relevant clinical activity. Aim of the present study is to investigate the efficacy of conventional weekly treatment using rituximab in gastric MALT NHL patients resistant/refractory or not suitable for eradication treatment, and to evaluate the relevance of the t(11; 18)(q21; q21) translocation and its possible role as a predictive criteria of response.

PATIENTS AND METHODS: Twenty-seven patients presenting with gastric MALT NHL at any stage, relapsed/refractory to initial treatment or not suitable for eradication were treated with rituximab in a weekly conventional schedule and evaluated for response and relapse. Flourescence in situ hybridization (FISH) analysis for the presence of 18q21 translocation was performed in 21 patients and was evaluated with clinical outcome.

RESULTS: Among the 26 evaluated patients, 20 (77%) achieved an objective response. Twelve patients (46%) had a pathological and clinical complete remission, and eight (31%) had a partial response. With a median follow-up of 33 months, only two patients relapsed at 26 and 14 months, respectively. No correlation was founded between FISH analysis and response or relapse.

CONCLUSION: Our experience seems to confirm the clinical activity of rituximab in gastric MALT NHL patients resistant/refractory to antibiotics treatment or not presenting with clinical evidence of Helicobacter pylori infection. The t(11; 18)(q21; q21) translocation seems not to be a predictive marker to response or to subsequent relapse.

G.M. and D.L. contributed equally to this article.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Stathis, C. Chini, F. Bertoni, I. Proserpio, C. Capella, L. Mazzucchelli, E. Pedrinis, F. Cavalli, G. Pinotti, and E. Zucca Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type Ann. Onc., June 1, 2009; 20(6): 1086 - 1093. [Abstract] [Full Text] [PDF]

				E. Zucca, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv113 - iv114. [Full Text] [PDF]

				P. G. Gobbi, F. Corbella, F. Valentino, M. Bergonzi, C. Sangalli, V. Perfetti, and G. R. Corazza Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy Ann. Onc., March 1, 2009; 20(3): 465 - 468. [Abstract] [Full Text] [PDF]

				M. P. Siakantaris, G. A. Pangalis, E. Dimitriadou, F. N. Kontopidou, T. P. Vassilakopoulos, C. Kalpadakis, S. Sachanas, X. Yiakoumis, P. Korkolopoulou, M.-C. Kyrtsonis, et al. Early-Stage Gastric MALT Lymphoma: Is It a Truly Localized Disease? Oncologist, February 1, 2009; 14(2): 148 - 154. [Abstract] [Full Text] [PDF]

				A. Psyrri, S. Papageorgiou, and T. Economopoulos Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management Ann. Onc., December 1, 2008; 19(12): 1992 - 1999. [Abstract] [Full Text] [PDF]

				G. Papaxoinis, G. Fountzilas, D. Rontogianni, M. A. Dimopoulos, N. Pavlidis, C. Tsatalas, D. Pectasides, N. Xiros, and T. Economopoulos Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG) Ann. Onc., April 1, 2008; 19(4): 780 - 786. [Abstract] [Full Text] [PDF]

				B. Kahl and D. Yang Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL Hematology, January 1, 2008; 2008(1): 359 - 364. [Abstract] [Full Text] [PDF]

				C. M Bacon, M.-Q. Du, and A. Dogan Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists J. Clin. Pathol., April 1, 2007; 60(4): 361 - 372. [Abstract] [Full Text] [PDF]

				S. M. Cohen, M. Petryk, M. Varma, P. S. Kozuch, E. D. Ames, and M. L. Grossbard Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue Oncologist, November 1, 2006; 11(10): 1100 - 1117. [Abstract] [Full Text] [PDF]

				M-Q Du and J C Atherton Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management. Gut, June 1, 2006; 55(6): 886 - 893. [Full Text] [PDF]

				T. Wundisch, C. Thiede, A. Morgner, A. Dempfle, A. Gunther, H. Liu, H. Ye, M.-Q. Du, T. D. Kim, E. Bayerdorffer, et al. Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter Pylori Eradication J. Clin. Oncol., November 1, 2005; 23(31): 8018 - 8024. [Abstract] [Full Text] [PDF]

				A. Salar, B. Bellosillo, S. Serrano, and C. Besses Persistent Residual Disease in t(11;18)(q21;q21) Positive Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Chemotherapy or Rituximab J. Clin. Oncol., October 10, 2005; 23(29): 7361 - 7362. [Full Text] [PDF]

				C. Thieblemont Clinical Presentation and Management of Marginal Zone Lymphomas Hematology, January 1, 2005; 2005(1): 307 - 313. [Abstract] [Full Text] [PDF]